… There is no doubt that the general principles of cancer therapeutics established over the
past 50 years remain valid. Combination treatment regimens covering multiple targets should …

… ), erlotinib (Tarceva), bevacizumab (Avastin), cetuximab (Erbitux), sorafenib (Nexavar),
and sunitinib (Sutent) have provided clinical validation for this molecularly targeted approach. …

… be clinically validated by the Phase 3 result. … clinical validation defines these rules for the
large number of moves and pieces which make up the very serious strategic contest of cancer …

… therapeutic approaches. In order to be applicable in a … focus is on the clinical validation,
validation of clinical utility and … Specifically, knowledge about the challenges to clinical validation …

… A major expectation for targeted molecular cancer therapeutics is that they show good …
Although it requires further experimental validation, this concept proposes that cancer cells …

… are likely to have a favorable clinical outcome, such as improved … focus on clinical trial designs
for predictive marker validation, … the rapid clinical validation of biomarker-guided therapy. …

… and clinical metastasis prevention data for FDA-approved breast cancer therapeutics … been
reported in the preclinical development and validation of metastasis clinical strategies. Many …

… the fact that the issue in cancer therapeutics is not whether a target is important or essential
in normal cells, but whether the target is more important in cancer cells than it is in normal …

… , was an oncogenic driver, and could be therapeutically targeted with clinical benefit. Post-clinical
validation using patient-derived model systems corroborated these findings, confirmed …

… In most instances, the biomarker is not clinically validated as a predictive marker (of efficacy)
early in the development of a new agent (ie, at the time of the phase II trial). The IDSC's …